Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer

Journal of Surgical Research

Volumn 185, Issue 2, 2013, Pages 676-683

  Wunderlich, Annette ^a   Khoruzhyk, Maryna ^a   Med, Cand ^a   Roth, Silvia ^a   Ramaswamy, Annette ^a   Greene, Brandon H ^a   Dipl Math, ^a   Doll, Dietrich ^b   Bartsch, Detlef K ^a   Hoffmann, Sebastian ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Marienhospital Vechta   (Germany)

Author keywords

Anaplastic thyroid cancer; Aurora kinase; Multikinase inhibitor; Patient derived human tumor tissue; Tailored tumor therapy; Xenografting

Indexed keywords

4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; CASPASE 3; HISTONE H3; SORAFENIB; VANDETANIB; VASCULOTROPIN RECEPTOR 2; BENZAZEPINE DERIVATIVE; CARBANILAMIDE DERIVATIVE; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; NICOTINAMIDE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; VASCULOTROPIN RECEPTOR; AURORA KINASE; DRUG DERIVATIVE; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 ((1 METHYLPIPERIDIN 4 YL)METHOXY)QUINAZOLIN 4 AMINE; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOL IN-4-AMINE;

ADULT; ANAPLASTIC THYROID CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; DRUG SCREENING; ENZYME ACTIVITY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MIDDLE AGED; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYROIDECTOMY; TUMOR CELL; TUMOR VASCULARIZATION; TUMOR VOLUME; TUMOR XENOGRAFT; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; CASE REPORT; CELL PROLIFERATION; DRUG EFFECTS; MALE; NEOVASCULARIZATION, PATHOLOGIC; NUDE MOUSE; PATHOLOGY; RANDOMIZATION; THYROID CARCINOMA; THYROID NEOPLASMS; TREATMENT OUTCOME; DRUG ANTAGONISM; DRUG EFFECT; MULTIKINASE INHIBITOR; NEOVASCULARIZATION (PATHOLOGY); PATIENT-DERIVED HUMAN TUMOR TISSUE XENOGRAFTING; TAILORED TUMOR THERAPY; THYROID TUMOR;

ANIMALS; APOPTOSIS; BENZAZEPINES; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; PHENYLUREA COMPOUNDS; PIPERIDINES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RANDOM ALLOCATION; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANAPLASTIC THYROID CANCER; AURORA KINASE; MULTIKINASE INHIBITOR; PATIENT-DERIVED HUMAN TUMOR TISSUE XENOGRAFTING; TAILORED TUMOR THERAPY;

EID: 84891818247     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2013.06.017     Document Type: Article

References (30)

1. Aschebrook-Kilfoy B, Ward MH, Sabra MM, Devesa SS. Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid 2011;21:125.
2. Lang BH, Lo CY. Surgical options in undifferentiated thyroid carcinoma. World J Surg 2007;31:969.
3. Nagaiah G, Hossain A, Mooney CJ, Parmentier J, Remick SC. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol 2011;2011:542358.
4. Foote RL, Molina JR, Kasperbauer JL, et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid 2011;21:25.
5. Orita Y, Sugitani I, Amemiya T, Fujimoto Y. Prospective application of our novel prognostic index in the treatment of anaplastic thyroid carcinoma. Surgery 2011;150:1212.
6. Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies [review]. Endocr Relat Cancer 2009;16:17.
7. Woyach JA, Shah MH. New therapeutic advances in the management of progressive thyroid cancer. Endocr Relat Cancer 2009;16:715.
8. Ha HT, Lee JS, Urba S, et al. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 2010;20:975.
9. Mooney CJ, Nagaiah G, Fu P, et al. A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 2009;19:233.
10. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr, Gandara DR. Aurora kinases as anticancer drug target. Clin Cancer Res 2008;14:1639.
11. Sorrentino R, Libertini S, Pallante PL, et al. Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab 2005;90: 928.
12. Ulisse S, Delcros JG, Baldini E, et al. Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues. Int J Cancer 2006;119:275.
13. Arlot-Bonnemains Y, Baldini E, Martin B, et al. Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines. Endocr Relat Cancer 2008;15:559.
14. Manfredi MG, Ecsedy JA, Meetze KA, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci USA 2007;104:4106.
15. Wunderlich A, Fischer M, Schlosshauer T, et al. Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer. Cancer Sci 2011;102:746.
16. Morabito A, Piccirillo MC, Falasconi F, et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions [review]. Oncologist 2009;14:378.
17. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64: 7099.
18. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008;7:3129.
19. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26:4714.
20. Jin K, Teng L, Shen Y, He K, Xu Z, Li G. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review. Clin Transl Oncol 2010;12:473.
21. Hoffmann S, Rockenstein A, Ramaswamy A, et al. Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells. Mol Cell Endocrinol 2007;264:74.
22. Puri M, Sen P. Nonparametric methods in multivariate analysis. New York: John Wiley & Sons; 1971.
23. Rubio-Viqueira B, Jimeno A, Cusatis G, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res 2006;12:4652.
24. Wang Y, Xue H, Cutz JC, et al. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest 2005; 85:1392.
25. Moretti L, Niermann K, Schleicher S, et al. MLN8054, a small molecule inhibitor of aurora kinase a, sensitizes androgen-resistant prostate cancer to radiation. Int J Radiat Oncol Biol Phys 2011;80:1189.
26. Wu W, Onn A, Isobe T, et al. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 2007; 6:471.
27. Cesca M, Frapolli R, Berndt A, et al. The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma. Neoplasia 2009;11:1155.
28. Hoffmann S, Gläser S, Wunderlich A, et al. Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors-a novel antiproliferative/antiangiogenic strategy in thyroid cancer. Langenbecks Arch Surg 2006;391:589.
29. Kim S, Yazici YD, Calzada G, et al. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol Cancer Ther 2007;6: 1785.
30. Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675.